Close Menu

NEW YORK (GenomeWeb) – Immunexpress, a privately held firm that has for several years been developing molecular assay technology to diagnose sepsis, may finally be close to marketing a clinical test in the US.

Having just wrapped up a key clinical trial of its first sepsis assay in around 200 ICU patients, Immunexpress plans to submit the test in May to the US Food and Drug Administration, and hopes it can gain marketing clearance by the end of this year, Immunexpress President and CEO Roslyn Brandon told GenomeWeb this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.

He Jiankui is no longer affiliated with Direct Genomics Biotechnology, the single molecule sequencing company he founded, Nikkei Asian Review reports.

Newsweek writes about the hopes for precision medicine in cancer, but also challenges getting it to patients.

In Genome Research this week: genomic architecture of glioblastoma, predictive computational approach to estimate SNP fitness, and more.